Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q3 2022 · 10-Q
Revenue$0.00$0.00no prior Q3 2021 on file Net Income-$13.24M-$13.24MN/M vs Q3 2021 EPS Diluted-$0.46-$0.46N/M vs Q3 2021 Operating Income-$13,492,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,707,000N/M ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end